Publication

Advances in Therapy publishes Pharma Two B’s review paper, “P2B001 (extended release pramipexole and rasagiline): A new treatment option in development for Parkinson’s disease”

by

Robert A. Hauser, Nir Giladi, Werner Poewe, Jonathan Brotchie, Hadas Friedman, Sheila Oren & Pninit Litman Published: 10 March 2022 Advances in TherapyDOI: 10.1007/s12325-022-02097-2 Abstract Despite levodopa’s superior efficacy in reducing the motor symptoms of Parkinson’s disease (PD), its risk to induce motor complications requires consideration of the pros and cons of initiating treatment with … Read more

A Randomized Trial of a Low Dose Rasagiline and Pramipexole Combination (P2B001) in Early Parkinson’s Disease

by

C. Warren Olanow MD, Karl Kieburtz MD, Mika Leinonen MSc, Lawrence Elmer MD, Nir Giladi MD, Robert A. Hauser MD, Olga S. Klepiskaya MD, David L. Kreitzman MD, Mark F. Lew MD, David S. Russell MD, Shaul Kadosh MSc, Pninit Litman PhD, Hadas Friedman MSc, Nurit Linvah PhD Published: 3 April 2017 Journal Movement Disorders DOI: 10.1002/mds.26941 … Read more

Pharma Two B Announces Positive Results in its Phase IIb Pivotal Clinical Study of P2B001 for the Treatment of Early Stage Parkinson’s Disease

by

Rehovoth, Israel, June 30, 2015 — Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs, announced today the successful results of the company’s Phase IIb pivotal study of P2B001 for the treatment of early stage Parkinson’s Disease (PD). P2B001 is a combination of low dose pramipexole and low … Read more

Pharma Two B taking ‘synergistic’ approach in pursuit of 505(b)(2) approval

by

Published in Scrip Magazine by Donna Young, April 22nd 2011 Israeli start-up Pharma Two B has taken the concept of synergism seriously, from the eclectic group of scientists and managers it has brought together under one roof, to its fixed-dose combination strategy of drug development, to the approval pathway it plans to seek in gaining … Read more